Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy
Authors
Keywords
-
Journal
Molecular Cancer
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-15
DOI
10.1186/s12943-020-01305-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II Multicenter, Open‐Label Study of Oral ENMD‐2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma
- (2020) Ghassan K. Abou‐Alfa et al. ONCOLOGIST
- Aurora Kinase A-YBX1 Synergy Fuels Aggressive Oncogenic Phenotypes and Chemoresistance in Castration-Resistant Prostate Cancer
- (2020) Kumar Nikhil et al. Cancers
- SDCBP/MDA-9/syntenin phosphorylation by AURKA promotes esophageal squamous cell carcinoma progression through the EGFR-PI3K-Akt signaling pathway
- (2020) Ruijuan Du et al. ONCOGENE
- MCPIP1 ribonuclease can bind and cleave AURKA mRNA in MYCN-amplified neuroblastoma cells
- (2020) Iwona Nowak et al. RNA Biology
- PUF60/AURKA Axis Contributes to Tumor Progression and Malignant Phenotypes in Bladder Cancer
- (2020) Qian Long et al. Frontiers in Oncology
- Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas
- (2019) Andrew Song et al. RADIOTHERAPY AND ONCOLOGY
- Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
- (2019) Owen A. O’Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined Aurora kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck
- (2019) Jong Woo Lee et al. CLINICAL CANCER RESEARCH
- Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells
- (2019) Müge Sak et al. JOURNAL OF NEURO-ONCOLOGY
- Phosphorylation of Merlin by Aurora A kinase appears necessary for mitotic progression
- (2019) Vinay Mandati et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)
- (2019) Zachary Veitch et al. Scientific Reports
- Aurora A selective inhibitor LY3295668 leads to dominant mitotic arrest, apoptosis in cancer cells and shows potent preclinical antitumor efficacy
- (2019) Jian Du et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma
- (2019) Steven I. Park et al. Targeted Oncology
- Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies
- (2019) Tanya Siddiqi et al. LEUKEMIA & LYMPHOMA
- BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells
- (2019) Matko Čančer et al. Cell Death & Disease
- Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation
- (2019) Ilaria Casari et al. Cancers
- Aurora-A mediated phosphorylation of LDHB promotes glycolysis and tumor progression by relieving the substrate-inhibition effect
- (2019) Aoxing Cheng et al. Nature Communications
- Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial
- (2019) Andrew M Brunner et al. Lancet Haematology
- GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells
- (2018) Małgorzata Durbas et al. APOPTOSIS
- A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
- (2018) Michael Carducci et al. INVESTIGATIONAL NEW DRUGS
- Polymer Nanovesicle-Mediated Delivery of MLN8237 Preferentially Inhibits Aurora Kinase A To Target RalA and Anchorage-Independent Growth in Breast Cancer Cells
- (2018) Siddhi Inchanalkar et al. MOLECULAR PHARMACEUTICS
- Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer
- (2018) Hayley J. Donnella et al. Nature Chemical Biology
- Phosphatase 1 Nuclear Targeting Subunit (PNUTS) Regulates Aurora Kinases and Mitotic Progression
- (2018) Feifei Wang et al. MOLECULAR CANCER RESEARCH
- c-Myc is a major determinant for antitumor activity of Aurora A kinase inhibitor MLN8237 in thyroid cancer
- (2018) Yiqi Li et al. THYROID
- Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells
- (2018) Changjie Wu et al. Nature Communications
- Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma
- (2018) Joshua Felgenhauer et al. NEOPLASIA
- PRL-3 promotes ubiquitination and degradation of AURKA and colorectal cancer progression via dephosphorylation of FZR1
- (2018) Cheng Zhang et al. CANCER RESEARCH
- Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1
- (2018) Lihong Wang-Bishop et al. GASTROENTEROLOGY
- Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
- (2018) Khyati N. Shah et al. NATURE MEDICINE
- Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer
- (2018) Gerald Falchook et al. JAMA Oncology
- Aurora A activation in mitosis promoted by BuGZ
- (2017) Yuejia Huang et al. JOURNAL OF CELL BIOLOGY
- SIX3, a tumor suppressor, inhibits astrocytoma tumorigenesis by transcriptional repression of AURKA/B
- (2017) Zhibin Yu et al. Journal of Hematology & Oncology
- Aurora Kinase A Promotes AR Degradation via the E3 Ligase CHIP
- (2017) Sukumar Sarkar et al. MOLECULAR CANCER RESEARCH
- Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
- (2017) Ana Alcaraz-Sanabria et al. MOLECULAR CANCER THERAPEUTICS
- Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration
- (2017) X Zheng et al. ONCOGENE
- FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells
- (2017) N Yang et al. ONCOGENE
- KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition
- (2017) Y Zhong et al. ONCOGENE
- Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL
- (2017) E Hasanov et al. ONCOGENE
- Translational upregulation of Aurora-A by hnRNP Q1 contributes to cell proliferation and tumorigenesis in colorectal cancer
- (2017) Chien-Hsien Lai et al. Cell Death & Disease
- Bone-in-culture array as a platform to model early-stage bone metastases and discover anti-metastasis therapies
- (2017) Hai Wang et al. Nature Communications
- Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer
- (2017) Anastasia A. Ionkina et al. Frontiers in Oncology
- Characterization of the Indirubin Derivative LDD970 as a Small Molecule Aurora Kinase A Inhibitor in Human Colorectal Cancer Cells
- (2017) Karyn Muzinga Ndolo et al. Immune Network
- Aurora A Phosphorylation of YY1 during Mitosis Inactivates its DNA Binding Activity
- (2017) Karen E. Alexander et al. Scientific Reports
- Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells
- (2016) Simona Daniele et al. ACS Chemical Neuroscience
- Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma
- (2016) M. A. Dickson et al. ANNALS OF ONCOLOGY
- In Vitro Characterization of Derrone as an Aurora Kinase Inhibitor
- (2016) Nhung Thi My Hoang et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors
- (2016) Julie N. Graff et al. CANCER
- Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells
- (2016) Si-Jia He et al. CANCER LETTERS
- Mitotic phosphorylation of SOX2 mediated by Aurora kinase A is critical for the stem-cell like cell maintenance in PA-1 cells
- (2016) Dandan Qi et al. CELL CYCLE
- Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
- (2016) Amir T. Fathi et al. HAEMATOLOGICA
- Tanshinone I induces human colorectal cancer cell apoptosis: The potential roles of Aurora A-p53 and survivin-mediated signaling pathways
- (2016) Mingjie Lu et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia
- (2016) Karen W. L. Yee et al. INVESTIGATIONAL NEW DRUGS
- Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial
- (2016) Steven G. DuBois et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases
- (2016) Wang Liu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma
- (2016) C. Kurokawa et al. JOURNAL OF NEURO-ONCOLOGY
- Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer
- (2016) V. K. Kozyreva et al. MOLECULAR CANCER THERAPEUTICS
- Aurora A kinase activates YAP signaling in triple-negative breast cancer
- (2016) S-S Chang et al. ONCOGENE
- A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia
- (2016) B. Vormoor et al. PEDIATRIC BLOOD & CANCER
- Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation
- (2016) Yung Chang Hsu et al. Oncotarget
- Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer
- (2016) Todd M. Pitts et al. Oncotarget
- Phosphorylation of CPAP by Aurora-A Maintains Spindle Pole Integrity during Mitosis
- (2016) En-Ju Chou et al. Cell Reports
- Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
- (2016) Amir T. Fathi et al. HAEMATOLOGICA
- A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors
- (2015) Patrick Schöffski et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
- (2015) Y. Liu et al. CLINICAL CANCER RESEARCH
- Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma
- (2015) K. M. Zullo et al. CLINICAL CANCER RESEARCH
- A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
- (2015) G. Borthakur et al. HAEMATOLOGICA
- A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors
- (2015) Manik Amin et al. INVESTIGATIONAL NEW DRUGS
- TPX2 phosphorylation maintains metaphase spindle length by regulating microtubule flux
- (2015) Jingyan Fu et al. JOURNAL OF CELL BIOLOGY
- Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108
- (2015) Paul M. Barr et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study
- (2015) Bohuslav Melichar et al. LANCET ONCOLOGY
- A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191
- (2015) Annette E. Hay et al. LEUKEMIA & LYMPHOMA
- Tanshinones suppress AURKA through up-regulation of miR-32 expression in non-small cell lung cancer
- (2015) Zhong-Liang Ma et al. Oncotarget
- A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
- (2015) G. Borthakur et al. HAEMATOLOGICA
- Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study
- (2014) P. Schoffski et al. ANNALS OF ONCOLOGY
- Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283
- (2014) William Petersen et al. CANCER LETTERS
- Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells
- (2014) A. E. Vilgelm et al. CANCER RESEARCH
- A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study
- (2014) L. Moreno et al. CLINICAL CANCER RESEARCH
- Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies
- (2014) Danielle C. Chinn et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships
- (2014) Karthik Venkatakrishnan et al. JOURNAL OF CLINICAL PHARMACOLOGY
- SAR156497, an Exquisitely Selective Inhibitor of Aurora Kinases
- (2014) Jean-Christophe Carry et al. JOURNAL OF MEDICINAL CHEMISTRY
- AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
- (2014) Emilia Caputo et al. Journal of Translational Medicine
- SMAD4 Suppresses AURKA-Induced Metastatic Phenotypes via Degradation of AURKA in a TGF -Independent Manner
- (2014) L. Jia et al. MOLECULAR CANCER RESEARCH
- A Novel Small Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor-Initiating Cells and Overcomes Drug Resistance
- (2014) F.-M. Zheng et al. MOLECULAR CANCER THERAPEUTICS
- Aurora-A enhances malignant development of esophageal squamous cell carcinoma (ESCC) by phosphorylating β-catenin
- (2014) Shunqian Jin et al. Molecular Oncology
- A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
- (2014) J F Seymour et al. Blood Cancer Journal
- Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer
- (2014) Channing J. Paller et al. Cancer Medicine
- Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma
- (2013) Markus Brockmann et al. CANCER CELL
- Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells
- (2013) Irena Horwacik et al. CANCER LETTERS
- NEDD9 Depletion Destabilizes Aurora A Kinase and Heightens the Efficacy of Aurora A Inhibitors: Implications for Treatment of Metastatic Solid Tumors
- (2013) R. J. Ice et al. CANCER RESEARCH
- NQO1 prevents radiation-induced aneuploidy by interacting with Aurora-A
- (2013) Moon-Taek Park et al. CARCINOGENESIS
- BimEL is phosphorylated at mitosis by Aurora A and targeted for degradation by βTrCP1
- (2013) M Moustafa-Kamal et al. CELL DEATH AND DIFFERENTIATION
- The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
- (2013) N. Zhou et al. CLINICAL CANCER RESEARCH
- HDM2 Regulation by AURKA Promotes Cell Survival in Gastric Cancer
- (2013) V. Sehdev et al. CLINICAL CANCER RESEARCH
- A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis
- (2013) James Foran et al. Clinical Lymphoma Myeloma & Leukemia
- A Novel Aurora-A Inhibitor, BPR1K0609S1, Sensitizes Colorectal Tumor cells to 5-Fluorofracil (5-FU) Treatment
- (2013) Yoshimi Shionome et al. International Journal of Biological Sciences
- A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors
- (2013) E. Raymond et al. INVESTIGATIONAL NEW DRUGS
- NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies
- (2013) S. F. Dent et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2013) Kevin R. Kelly et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas
- (2013) Jonathan W. Friedberg et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies
- (2013) Carlos Graux et al. LEUKEMIA RESEARCH
- Inhibition of mTOR Pathway Sensitizes Acute Myeloid Leukemia Cells to Aurora Inhibitors by Suppression of Glycolytic Metabolism
- (2013) L.-L. Liu et al. MOLECULAR CANCER RESEARCH
- Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion
- (2013) T-V Do et al. ONCOGENE
- Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer
- (2013) X Q Zheng et al. ONCOGENE
- Integrity of p53 Associated Pathways Determines Induction of Apoptosis of Tumor Cells Resistant to Aurora-A Kinase Inhibitors
- (2013) Yoshimi Shionome et al. PLoS One
- Identification of pVHL as a Novel Substrate for Aurora-A in Clear Cell Renal Cell Carcinoma (ccRCC)
- (2013) Benedicte Martin et al. PLoS One
- Small Molecule R1498 as a Well-Tolerated and Orally Active Kinase Inhibitor for Hepatocellular Carcinoma and Gastric Cancer Treatment via Targeting Angiogenesis and Mitosis Pathways
- (2013) Chao Zhang et al. PLoS One
- A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors
- (2013) M. Mita et al. Targeted Oncology
- The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumoursin vitro
- (2013) K. Shiomitsu et al. Veterinary and Comparative Oncology
- A novel Aurora-A-mediated phosphorylation of p53 inhibits its interaction with MDM2
- (2012) Kai-Wei Hsueh et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure
- (2012) Hielke J. Meulenbeld et al. BJU INTERNATIONAL
- Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells
- (2012) Warren Fiskus et al. BREAST CANCER RESEARCH AND TREATMENT
- Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
- (2012) Y Lin et al. BRITISH JOURNAL OF CANCER
- The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas
- (2012) Vikas Sehdev et al. CANCER
- Aurora Kinase-A Inactivates DNA Damage-Induced Apoptosis and Spindle Assembly Checkpoint Response Functions of p73
- (2012) Hiroshi Katayama et al. CANCER CELL
- Chromosome Instability Modulated by BMI1-AURKA Signaling Drives Progression in Head and Neck Cancer
- (2012) C.-H. Chou et al. CANCER RESEARCH
- The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent
- (2012) Jayasree S. Nair et al. CELL CYCLE
- Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study
- (2012) Y. P. Mosse et al. CLINICAL CANCER RESEARCH
- A Small-Molecule Inhibitor Targeting the Mitotic Spindle Checkpoint Impairs the Growth of Uterine Leiomyosarcoma
- (2012) W. Shan et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2012) A. Cervantes et al. CLINICAL CANCER RESEARCH
- Dual Targeting of mTOR and Aurora-A Kinase for the Treatment of Uterine Leiomyosarcoma
- (2012) K. J. Brewer Savannah et al. CLINICAL CANCER RESEARCH
- Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models
- (2012) J. R. Diamond et al. CLINICAL CANCER RESEARCH
- Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma
- (2012) D. Mahadevan et al. CLINICAL CANCER RESEARCH
- Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model
- (2012) K. Fraedrich et al. CLINICAL CANCER RESEARCH
- Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
- (2012) E. C. Dees et al. CLINICAL CANCER RESEARCH
- Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence
- (2012) Yan Liu et al. EMBO Molecular Medicine
- ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer
- (2012) Ursula A. Matulonis et al. EUROPEAN JOURNAL OF CANCER
- Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
- (2012) Ursula A. Matulonis et al. GYNECOLOGIC ONCOLOGY
- Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism
- (2012) Kevin R. Kelly et al. INTERNATIONAL JOURNAL OF CANCER
- LIMK2 is a crucial regulator and effector of Aurora-A-kinase-mediated malignancy
- (2012) E. O. Johnson et al. JOURNAL OF CELL SCIENCE
- Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells
- (2012) Sujatha Venkataraman et al. JOURNAL OF NEURO-ONCOLOGY
- MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia
- (2012) F J Giles et al. LEUKEMIA
- Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase a oncogene
- (2012) Maria Meehan et al. Molecular Cancer
- The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells
- (2012) V. Sehdev et al. MOLECULAR CANCER THERAPEUTICS
- Ashwagandha Derived Withanone Targets TPX2-Aurora A Complex: Computational and Experimental Evidence to its Anticancer Activity
- (2012) Abhinav Grover et al. PLoS One
- Tanshinones Inhibit the Growth of Breast Cancer Cells through Epigenetic Modification of Aurora A Expression and Function
- (2012) Yi Gong et al. PLoS One
- Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma
- (2011) Wenqing Qi et al. BIOCHEMICAL PHARMACOLOGY
- Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
- (2011) Hernan Carol et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
- (2011) L. Kretzner et al. CANCER RESEARCH
- Aurora A Is a Repressed Effector Target of the Chromatin Remodeling Protein INI1/hSNF5 Required for Rhabdoid Tumor Cell Survival
- (2011) S. Lee et al. CANCER RESEARCH
- Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway
- (2011) Ilana Chefetz et al. CELL CYCLE
- Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide
- (2011) L. Santo et al. CLINICAL CANCER RESEARCH
- Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours
- (2011) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas
- (2011) Wenqing Qi et al. INTERNATIONAL JOURNAL OF CANCER
- MLN8054, A Small Molecule Inhibitor of Aurora Kinase A, Sensitizes Androgen-Resistant Prostate Cancer to Radiation
- (2011) Luigi Moretti et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Ubiquitin-specific Cysteine Protease 2a (USP2a) Regulates the Stability of Aurora-A
- (2011) Yan Shi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer
- (2011) E. O. Johnson et al. JOURNAL OF CELL SCIENCE
- The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo
- (2011) A. Faisal et al. MOLECULAR CANCER THERAPEUTICS
- Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death
- (2011) V Ratushny et al. ONCOGENE
- A Translational Regulator, PUM2, Promotes Both Protein Stability and Kinase Activity of Aurora-A
- (2011) Yei-Hsuan Huang et al. PLoS One
- BPR1K653, a Novel Aurora Kinase Inhibitor, Exhibits Potent Anti-Proliferative Activity in MDR1 (P-gp170)-Mediated Multidrug-Resistant Cancer Cells
- (2011) Chun Hei Antonio Cheung et al. PLoS One
- Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells
- (2010) R. Tanaka et al. BLOOD
- A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma
- (2010) Xiaojing Wang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
- (2010) E. Claire Dees et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
- (2010) Anne M. Traynor et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines
- (2010) M. Payton et al. CANCER RESEARCH
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors
- (2010) J. R. Diamond et al. CLINICAL CANCER RESEARCH
- Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line-Derived Human Colorectal Cancer Xenograft Models
- (2010) J. J. Tentler et al. CLINICAL CANCER RESEARCH
- Control of Aurora-A stability through interaction with TPX2
- (2010) M. Giubettini et al. JOURNAL OF CELL SCIENCE
- Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification
- (2010) Mohane Selvaraj Coumar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Imidazo[4,5-b]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidate
- (2010) Vassilios Bavetsias et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics
- (2010) T. Macarulla et al. MOLECULAR CANCER THERAPEUTICS
- ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action
- (2010) G. C. Fletcher et al. MOLECULAR CANCER THERAPEUTICS
- MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
- (2010) T. Shimomura et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core
- (2010) Tao Yu et al. ACS Medicinal Chemistry Letters
- Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia
- (2009) Nicholas J. Donato et al. BIOCHEMICAL PHARMACOLOGY
- Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
- (2009) D. Hose et al. BLOOD
- A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
- (2009) R. B. Cohen et al. CLINICAL CANCER RESEARCH
- Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells
- (2009) T.-L. Cha et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors
- (2009) Neeltje Steeghs et al. JOURNAL OF CLINICAL ONCOLOGY
- An essential role of the aPKC–Aurora A–NDEL1 pathway in neurite elongation by modulation of microtubule dynamics
- (2009) Daisuke Mori et al. NATURE CELL BIOLOGY
- Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate
- (2008) Y. Dai et al. BLOOD
- Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
- (2008) A. Gontarewicz et al. BLOOD
- Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia
- (2008) K. Kojima et al. BLOOD
- Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth
- (2008) Y. G. Lin et al. CLINICAL CANCER RESEARCH
- Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells
- (2008) W. Fiskus et al. CLINICAL CANCER RESEARCH
- Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines
- (2008) Y. Arlot-Bonnemains et al. ENDOCRINE-RELATED CANCER
- The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
- (2008) Zhong-Zhe Lin et al. JOURNAL OF HEPATOLOGY
- A Pentacyclic Aurora Kinase Inhibitor (AKI-001) with High in Vivo Potency and Oral Bioavailability∞
- (2008) Thomas E. Rawson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity†
- (2008) Steven Howard et al. JOURNAL OF MEDICINAL CHEMISTRY
- Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells
- (2008) A. M. D'Alise et al. MOLECULAR CANCER THERAPEUTICS
- Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
- (2008) Libor Macůrek et al. NATURE
- Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression
- (2008) Liang-Yi Hung et al. NUCLEIC ACIDS RESEARCH
- RASSF1A interacts with and activates the mitotic kinase Aurora-A
- (2008) L Liu et al. ONCOGENE
- Pituitary tumor transforming gene 1 regulates Aurora kinase A activity
- (2008) Y Tong et al. ONCOGENE
- The aurora kinase A regulates GSK-3β in gastric cancer cells
- (2008) A A Dar et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now